Skip to main content

FDA Approves Sensipar

Sensipar Amgen Inc. - Treatment for Secondary Hyperparathyroidism in dialysis patients

Sensipar is a first-in-class oral calcimimetic indicated for the treatment of secondary hyperparathyroidism (secondary HPT) in chronic kidney disease (CKD) patients on dialysis, and the treatment of elevated calcium levels (hypercalcemia) in patients with parathyroid carcinoma.

Sensipar (cinacalcet) FDA Approval History

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.